Acepodia

Acepodia is a clinical-stage biotechnology company focused on developing first-in-class cell therapies for cancer and autoimmune diseases. The company utilizes its proprietary Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) technology platforms, which are based on Nobel Prize-winning bioorthogonal chemistry, to link tumor-targeting antibodies to immune cells like gamma delta T cells and natural killer (NK) cells. By enhancing the binding strength and potency of these immune cells, Acepodia aims to create off-the-shelf, accessible, and effective therapies that address significant gaps in oncology and autoimmune care. The company maintains a global presence with operations in Alameda, California, and Taipei, Taiwan.